首页> 外文OA文献 >FRI0077 SHORT DURATION OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (CSDMARDS) BEFORE AND AFTER BECOMING A CSDMARD INADEQUATE RESPONDER IN RHEUMATOID ARTHRITIS PATIENTS

【2h】

FRI0077 SHORT DURATION OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (CSDMARDS) BEFORE AND AFTER BECOMING A CSDMARD INADEQUATE RESPONDER IN RHEUMATOID ARTHRITIS PATIENTS

机译：Fri0077在随后成为类风湿性关节炎患者的CSDARD响应不足之前和之后，Fri0077常规合成疾病改性抗风湿药物（CSDMARDS）的持续时间短

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Robin K Dore; Jenya Antonova; Huang Huan; Magdaliz Gorritz; Mark C. Genovese;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI) [J] . Doerner T., Schulze-Koops H., Burmester G. -R., Clinical and experimental rheumatology . 2019,第6期

机译：类风湿性关节炎患者的早期和晚期反应是常规的合成疾病改性抗风湿药物不足的响应者，并用TOCOLIZUAB处理或切换到Rituximab：开放标签第3阶段试验（MIRAI）
2. Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study [J] . Mueller Ruediger B., Graninger Winfried, Sidiropoulos Paris, Clinical rheumatology . 2017,第10期

机译：与CSDMARDS相比，与CSDMAB单药治疗有活性类风湿性关节炎患者的患者，对CSDMARDS和/或TNF抑制剂的反应不足，中间疾病活动较短，与CSDMAB单药疗法相比学习
3. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial [J] . Burmester Gerd R., Kremer Joel M., Van den Bosch Filip, The Lancet . 2018,第10139期

机译：upadacitinib在类风湿性关节炎患者中的安全性和疗效和对常规合成疾病改性抗风湿药物的反应不足（选择 - 下一步）：随机，双盲，安慰剂控制第3期试验
4. The Efficacy of Therapeutic Drug Monitoring of Rheumatoid Arthritis Patients on Infliximab [D] . Abolhosn, Rania. 2018

机译：类风湿性关节炎患者治疗药物监测对英夫利昔单抗的疗效
5. Efficacy and safety of baricitinib for active rheumatoid arthritis in patients with an inadequate response to conventional synthetic or biological disease-modifying anti-rheumatic drugs: A meta-analysis of randomized controlled trials [O] . Zhi-Peng Wu, Pei Zhang, Jian-Zhong Bai, -1

机译：对传统的合成或可改变生物疾病的抗风湿药反应不足的患者Baricitinib治疗活动性类风湿关节炎的疗效和安全性：一项随机对照试验的荟萃分析
6. PDG70 SHORT DURATION OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (CSDMARDS) BEFORE AND AFTER BECOMING A CSDMARD INADEQUATE RESPONDER (IR) IN RHEUMATOID ARTHRITIS (RA) PATIENTS [O] . R.K. Dore, J. Antonova, H. Huang, 2019

机译：PDG70之前和之后常规合成疾病改性抗风湿药物（CSDMARDS）的持续时间，成为类风湿性关节炎（RA）患者的CSDMARD响应者（IR）

FRI0077 SHORT DURATION OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (CSDMARDS) BEFORE AND AFTER BECOMING A CSDMARD INADEQUATE RESPONDER IN RHEUMATOID ARTHRITIS PATIENTS

著录项

引文网络

相似文献

相关主题

期刊订阅